Localizarea bolilor
Pachete de Analize
Analize de laborator
Contact

Molecular genetic tests

Home Personalized medicine Molecular genetic tests

PROSIGNA ™

Molecular genetic testing for breast cancer

The Prosigna test is a diagnostic test capable of classifying breast tumors into several clinical subtypes to assess the risk of recurrence (ROR) over the next 10 years in patients with early-stage breast cancer.

  • Prognosis in breast cancer, progressing, recurrences or total cure;
  • It allows therapy based on molecular diagnosis;
  • PALM 50, the largest number of genes studied;
  • Prediction for 10 years.

Prosigna și subtipurile intrinseci

Prosigna ™ (PAM50) is a molecular test that measures the expression of 50 genes to characterize the tumor and allow its classification into one of 4 intrinsic subtypes:

Luminal A                       Luminal B

Her2-positive                    Basal

Intrinsic subtypes are related to disease prognosis

Intrinsic subtypes are related to disease prognosis and each subtype is characterized by a different gene expression profile, which will mean a different distant recurrence risk and survival rate.

Prosigna is the test that determines the intrinsic subtype of the tumor.

The intrinsic subtype is decisive in assessing prognosis and a key factor in determining treatment.

The Prosigna test measures the expression of 50 different genes to identify the subtype of the breast tumor and to calculate the Recurrence Risk Score (RRIS) in order to place the patient in a risk group for distant recurrence.

The result is obtained based on an algorithm based on the expression of the 50 genes, the intrinsic subtype, as well as clinical data, tumor size and lymph node status.

Recurrence Risk Score (ROR)

Recurrence Risk Score (ROR) is expressed by a number in the range of 0 to 100, which is then correlated with the Recurrence at Distance (RD) to interpret the result.

Depending on the ROR value, the patients will fall into groups of low, intermediate or high risk of recurrence.

Prosigna ™ determines the probability of a recurrence at a distance of up to 10 years and characterizes the intrinsic subtype.

Directions

The test is indicated for women who have been surgically treated for breast cancer with the following characteristics:

  • – Hormone receptor positive (HR+), lymph node negative, Stage I or II breast cancer
  • – Hormone receptor positive (HR+), lymph node positive (1-3 nodes or 4 or more), Stage II or IIIA breast cancer.

What is required to take the test?

Sample: tumor tissue fixed in formalin and embedded in paraffin or unstained slides, with the area of invasive breast carcinoma marked.

The patient can contact us directly based on the doctor's referral and is advised and accompanied by us, from the beginning of the procedure for granting the voucher until receiving the result.

The Prosigna ™ test is included in the ASSMB Project "Genetic testing for breast cancer in early stages" which provides financial support for carrying out genetic tests for people diagnosed with breast cancer in early stages.

The amount allocated is 17,000 lei/beneficiary, in the form of vouchers, for approximately 1000 beneficiaries, domiciled in Bucharest.